IXC
Pharmaceuticals, Biotechnology & Life Sciences
Invex Therapeutics
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 1 Oct 2025
- Reported shorts
- 3.5K
- Shares on issue
- 75.154M
Invex Therapeutics (IXC) company profile
Profile, insiders and operations
Company
AI-generated research profile of Invex Therapeutics
Biopharmaceuticals
Neurological Conditions
Drug Development
ICP Treatment
Exenatide
Invex Therapeutics is a biopharmaceutical company focused on developing treatments for neurological conditions caused by raised intracranial pressure (ICP). The company is repurposing the drug Exenatide, trademarked as Presendin™, to address this significant unmet medical need. Invex aims to leverage its research and development expertise to provide efficacious solutions for conditions like idiopathic intracranial hypertension and traumatic brain injury.
IXC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required